The role of artificial intelligence in pharmacy: Revolutionizing drug development and beyond

Abstract

Artificial intelligence (AI) is revolutionizing drug development by expediting the discovery, formulation, and testing of potential treatments. By analyzing vast datasets, such as genetic information, AI algorithms pinpoint disease targets and predict drug interactions, accelerating the entire process. This reduces reliance on extensive animal testing, leading to faster development and potentially higher approval rates. AI optimizes costs by streamlining research, predicting drug behavior, and designing better experiments, reducing the need for costly animal testing. Moreover, AI analyzes real-world patient data to personalize drug treatments, potentially improving adherence and outcomes. This comprehensive overview of AI in drug development covers discovery, delivery, dosage form design, process optimization, testing, and pharmacokinetic/pharmacodynamic investigations. It assesses the strengths and weaknesses of AI techniques in pharmaceutical technology while acknowledging potential limitations. The pursuit of more potent and stable drugs to address unmet medical needs is a key goal. However, addressing concerns over toxicity necessitates further investigation. Developing therapeutic molecules with optimal properties for healthcare use remains a priority. Yet, the pharmacy sector faces challenges requiring further development through technology-driven approaches to meet global medical and healthcare demands. This review aims to discuss the role of AI in the field of pharmacy.

Keywords

artificial intelligence / drug development / drug discovery / machine learning / pharmacovigilance / pharmacy

References

[1] Singh M, Khushtar M, Ajmal M. Drug utilization pattern and adverse drug reaction monitoring of drugs used in typhoid at a tertiary care hospital: a prospective observational study. World J Pharm Pharmaceut Sci. 2023; 12(7): 1462-1470.

[2] Shams AR, Ajmal M, Basit A, Khan AN. Assessment of compliance of antimicrobial agents used in the surgical prophylaxis for clean cases surgery at a tertiary care hospital, India. World J Pharm Pharmaceut Sci. 2023; 12(7): 1579-1589.

[3] Khan A, Nematullah M, Fatima N, Perween S, Ebadurrahman . Ebadurrahman. Guillain-barré syndrome (GBS) with compressive myelopathy: a case report. Intell Pharm. 2023; 1(4): 283-285. https://doi.org/10.1016/J.IPHA.2023.07.004

[4] Fatima N, Perween S, Ansari S, et al. Study of drugs prescribed and adverse drug reaction in polycystic ovary syndrome and menstrual disorders in gynaecology department at Integral Institute of Medical Sciences and Research, Lucknow, India. Int J Adv Res. 2023; 11(8): 848-858. https://doi.org/10.21474/IJAR01/17461

[5] Sada M, Khan S, Khan MU, Khan MM, Kumar P, Ahmad U. Drug utilization and prescribing pattern in the treatment of urolithiasis: a perspective on World Health Organization recommendations. Int J Basic Clin Pharmacol. 2024; 13(3): 371-377. https://doi.org/10.18203/2319-2003.IJBCP20240994

[6] Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021; 26(1): 80-93. https://doi.org/10.1016/J.DRUDIS.2020.10.010

[7] Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics. 2023; 15(7): 1916-1924. https://doi.org/10.3390/PHARMACEUTICS15071916

[8] Raj A, Mukherjee AA, de Sousa Jabbour ABL, Srivastava SK. Supply chain management during and post-COVID-19 pandemic: mitigation strategies and practical lessons learned. J Bus Res. 2022; 142: 1125-1142. https://doi.org/10.1016/J.JBUSRES.2022.01.037

[9] Chavda VP, Valu DD, Parikh PK, et al. Conventional and novel diagnostic tools for the diagnosis of emerging SARS-CoV-2 variants. Vaccines. 2023; 11(2): 374-382. https://doi.org/10.3390/VACCINES11020374

[10] Serrano DR, Luciano FC, Anaya BJ, et al. Artificial intelligence (AI) applications in drug discovery and drug delivery: revolutionizing personalized medicine. Pharmaceutics. 2024; 16(10): 1328-1341. https://doi.org/10.3390/PHARMACEUTICS16101328

[11] Dhudum R, Ganeshpurkar A, Pawar A. Revolutionizing drug discovery: a comprehensive review of AI applications. Drugs Drug Candidates. 2024; 3(1): 148-171. https://doi.org/10.3390/DDC3010009

[12] Alowais SA, Alghamdi SS, Alsuhebany N, et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Med Educ. 2023; 23(1): 1-15. https://doi.org/10.1186/S12909-023-04698-Z

[13] Sacha GM, Varona P. Artificial intelligence in nanotechnology. Nanotechnology (Bristol). 2013; 24(45): 452002-452009. https://doi.org/10.1088/0957-4484/24/45/452002

[14] Cerón-Carrasco JP. When virtual screening yields inactive drugs: dealing with false theoretical friends. ChemMedChem. 2022; 17(16):e202200283. https://doi.org/10.1002/CMDC.202200278

[15] Faure A, York P, Rowe RC. Process control and scale-up of pharmaceutical wet granulation processes: a review. Eur J Pharm Biopharm. 2001; 52(3): 269-277. https://doi.org/10.1016/S0939-6411(01)00184-9

[16] Landin M. Artificial intelligence tools for scaling up of high shear wet granulation process. J Pharmaceut Sci. 2017; 106(1): 273-277. https://doi.org/10.1016/J.XPHS.2016.09.022

[17] Das MK, Chakraborty T. Artif Neural Netw Drug Des Deliv Dispos; 2016: 277-293. Published online. https://doi.org/10.1016/B978-0-12-801559-9.00014-4. ANN in pharmaceutical product and process development.

[18] Gams M, Horvat M, Ožek M, Luštrek M, Gradišek A. Integrating artificial and human intelligence into tablet production process. AAPS PharmSciTech. 2014; 15(6): 1447-1453. https://doi.org/10.1208/S12249-014-0174-Z

[19] Rantanen J, Khinast J. The future of pharmaceutical manufacturing sciences. J Pharmaceut Sci. 2015; 104(11): 3612-3638. https://doi.org/10.1002/JPS.24594

[20] Ding M, Eliashberg J, Stremersch S. International Series in Quantitative Marketing Innovation and Marketing in the Pharmaceutical Industry. Vol 1. Springer Science+Business Media; 2014. https://doi.org/10.1007/978-1-4614-7801-0_7

[21] Bain EE, Shafner L, Walling DP, et al. Use of a novel artificial intelligence platform on mobile devices to assess dosing compliance in a phase 2 clinical trial in subjects with schizophrenia. JMIR mHealth uHealth. 2017; 5(2): e18-e27. https://doi.org/10.2196/MHEALTH.7030

[22] Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017; 389(10064): 67-76. https://doi.org/10.1016/S0140-6736(16)32455-2

[23] Wang J, Wang H, Wang X, Chang H. Predicting drug-target interactions via fm-dnn learning. Curr Bioinf. 2020; 15(1): 68-76. https://doi.org/10.2174/1574893614666190227160538

[24] Sharma A, Virmani T, Pathak V, et al. Artificial intelligence-based data-driven strategy to accelerate research, development, and clinical trials of COVID vaccine. BioMed Res Int. 2022; 2022(1):7205241. https://doi.org/10.1155/2022/7205241

[25] Ong E, Wong MU, Huffman A, He Y. COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning. Front Immunol. 2020; 11: 1581-1595. https://doi.org/10.3389/FIMMU.2020.01581/BIBTEX

[26] Prachar M, Justesen S, Steen-Jensen DB, et al. Identification and validation of 174 COVID-19 vaccine candidate epitopes reveals low performance of common epitope prediction tools. Sci Rep. 2020; 10(1): 1-8. https://doi.org/10.1038/s41598-020-77466-4

[27] Lv H, Shi L, Berkenpas JW, et al. Application of artificial intelligence and machine learning for COVID-19 drug discovery and vaccine design. Briefings Bioinf. 2021; 22(6): bbab320. https://doi.org/10.1093/BIB/BBAB320

[28] Yang Z, Bogdan P, Nazarian S. An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study. Sci Rep. 2021; 11(1): 1-21. https://doi.org/10.1038/s41598-021-81749-9

[29] Oza RR, Domadiya DH. Analysis of unstructured data using artificial intelligence. Int J Creat Res Thoughts. 2023; 11(5): i969-i973.

[30] Mockute R, Desai S, Perera S, et al. Artificial intelligence within pharmacovigilance: a means to identify cognitive services and the framework for their validation. Pharmaceut Med. 2019; 33(2): 109-120. https://doi.org/10.1007/S40290-019-00269-0

[31] Basile AO, Yahi A, Tatonetti NP. Artificial intelligence for drug toxicity and safety. Trends Pharmacol Sci. 2019; 40(9): 624-635. https://doi.org/10.1016/J.TIPS.2019.07.005

[32] Prakash J, Sachdeva R, Shrivastava TP, Jayachandran CV, Sahu A. Adverse event reporting tools and regulatory measures in India through outcome of pharmacovigilance programme of India. Indian J Pharmacol. 2021; 53(2): 143-152. https://doi.org/10.4103/IJP.IJP_901_20

[33] Desai MK. Artificial intelligence in pharmacovigilance - opportunities and challenges. Perspect Clin Res. 2024; 15(3): 116-121. https://doi.org/10.4103/PICR.PICR_290_23

[34] Alkubaisy MM, Hashim DJ, Shakir KH, et al. AI in neurodegenerative disease research: IBM Watson identifying RNA binding proteins. In: International Conference on IoT, Communication and Automation Technology (ICICAT). IEEE; 2024: 669-674. https://doi.org/10.1109/ICICAT62666.2024.10923068

[35] Donner Y, Kazmierczak S, Fortney K. Drug repurposing using deep embeddings of gene expression profiles. Mol Pharm. 2018; 15(10): 4314-4325. https://doi.org/10.1021/ACS.MOLPHARMACEUT.8B00284/ASSET/IMAGES/MEDIUM/MP-2018-002845_0004.GIF

[36] Alqahtani A. Application of artificial intelligence in discovery and development of anticancer and antidiabetic therapeutic agents. Evid Based Complement Alternat Med. 2022; 2022:6201067. https://doi.org/10.1155/2022/6201067

[37] Raies AB, Bajic VB. In silico toxicology: computational methods for the prediction of chemical toxicity. Wiley Interdiscip Rev Comput Mol Sci. 2016; 6(2): 147-172. https://doi.org/10.1002/WCMS.1240

[38] Onakpoya IJ, Heneghan CJ, Aronson JK. Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis. Crit Rev Toxicol. 2016; 46(6): 477-489. https://doi.org/10.3109/10408444.2016.1149452

[39] Segall MD, Barber C. Addressing toxicity risk when designing and selecting compounds in early drug discovery. Drug Discov Today. 2014; 19(5): 688-693. https://doi.org/10.1016/J.DRUDIS.2014.01.006

[40] Lo YC, Rensi SE, Torng W, Altman RB. Machine learning in chemoinformatics and drug discovery. Drug Discov Today. 2018; 23(8): 1538-1546. https://doi.org/10.1016/J.DRUDIS.2018.05.010

[41] Lu J, Lu D, Fu Z, Zheng M, Luo X. Machine learning-based modeling of drug toxicity. Methods Mol Biol. 2018; 1754: 247-264. https://doi.org/10.1007/978-1-4939-7717-8_15

[42] Linden A, Yarnold PR, Nallamothu BK. Using machine learning to model dose-response relationships. J Eval Clin Pract. 2016; 22(6): 856-863. https://doi.org/10.1111/JEP.12573

[43] Han R, Yang Y, Li X, Ouyang D. Predicting oral disintegrating tablet formulations by neural network techniques. Asian J Pharm Sci. 2018; 13(4): 336-342. https://doi.org/10.1016/J.AJPS.2018.01.003

[44] Akseli I, Xie J, Schultz L, et al. A practical framework toward prediction of breaking force and disintegration of tablet formulations using machine learning tools. J Pharmaceut Sci. 2017; 106(1): 234-247. https://doi.org/10.1016/J.XPHS.2016.08.026

[45] Aronson JK, Heneghan C, Ferner RE. Medical devices: definition, classification, and regulatory implications. Drug Saf. 2020; 43(2): 83-93. https://doi.org/10.1007/S40264-019-00878-3

[46] Opderbeck D. Artificial intelligence in pharmaceuticals, biologics, and medical devices: present and future regulatory models. Fordham Law Rev. 2019; 88(2): 44-57.

[47] Pesapane F, Volonté C, Codari M, Sardanelli F. Artificial intelligence as a medical device in radiology: ethical and regulatory issues in Europe and the United States. Insights Imaging. 2018; 9(5): 745-753. https://doi.org/10.1007/S13244-018-0645-Y/TABLES/5

[48] Yaeger KA, Martini M, Yaniv G, Oermann EK, Costa AB. United States regulatory approval of medical devices and software applications enhanced by artificial intelligence. Heal Policy Technol. 2019; 8(2): 192-197. https://doi.org/10.1016/J.HLPT.2019.05.006

[49] Bedenkov A, Moreno C, Agustin L, et al. Customer centricity in medical affairs needs human-centric artificial intelligence. Pharmaceut Med. 2021; 35(1): 21-29. https://doi.org/10.1007/S40290-020-00378-1

[50] Dobariya P, Chandrakantbhai Vaghela M, Bhagwan Deshpande P, et al. Harnessing artificial intelligence and machine learning in six-sigma documentation for pharmaceutical quality assurance. J Chem Heal Risks. 2024; 14(3): 2753-2766. https://doi.org/10.52783/JCHR.V14.I3.5036

[51] Jalkala AM, Keränen J. Brand positioning strategies for industrial firms providing customer solutions. J Bus Ind Mark. 2014; 29(3): 253-264. https://doi.org/10.1108/JBIM-10-2011-0138

[52] Yılmaz BÖ, Tozan H, Karadayı MA. Multi-criteria decision making (MCDM) applications in military healthcare field. J Heal Syst Policies. 2020; 2(2): 149-181.

[53] Singh J, Flaherty K, Sohi RS, et al. Sales profession and professionals in the age of digitization and artificial intelligence technologies: concepts, priorities, and questions. J Personal Sell Sales Manag. 2019; 39(1): 2-22. https://doi.org/10.1080/08853134.2018.1557525

[54] Xu Y, Ahokangas P, Louis JN, Pongrácz E. Electricity market empowered by artificial intelligence: a platform approach. Energies. 2019; 12(21): 4128-4137. https://doi.org/10.3390/EN12214128

[55] Syam N, Sharma A. Waiting for a sales renaissance in the fourth industrial revolution: machine learning and artificial intelligence in sales research and practice. Ind Mark Manag. 2018; 69: 135-146. https://doi.org/10.1016/J.INDMARMAN.2017.12.019

[56] Nilesh Mahajan K, Kumar A. Business intelligent smart sales prediction analysis for pharmaceutical distribution and proposed generic model. Int J Comput Sci Inf Technol. 2017; 8(3): 407-412.

[57] Duran O, Rodriguez N, Consalter LA. Neural networks for cost estimation of shell and tube heat exchangers. Expert Syst Appl. 2009; 36(4): 7435-7440. https://doi.org/10.1016/J.ESWA.2008.09.014

[58] Park Y, Goto D, Yang KF, et al. A literature review of factors affecting price and competition in the global pharmaceutical market. Value Health. 2016; 19(3): A265-A278. https://doi.org/10.1016/j.jval.2016.03.816

[59] Chauhan V, Rai V, Singh S. The globalization of the pharmaceutical industry: trends and implications. IASR J Med Pharm Sci. 2024; 4(4): 199-203.

[60] Siepmann J, Siepmann F. Modeling of diffusion controlled drug delivery. J Control release. 2012; 161(2): 351-362. https://doi.org/10.1016/J.JCONREL.2011.10.006

[61] Yang SY, Huang Q, Li LL, et al. An integrated scheme for feature selection and parameter setting in the support vector machine modeling and its application to the prediction of pharmacokinetic properties of drugs. Artif Intell Med. 2009; 46(2): 155-163. https://doi.org/10.1016/J.ARTMED.2008.07.001

[62] Avdeef A, Artursson P, Neuhoff S, Lazorova L, Gråsjö J, Tavelin S. Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKa(flux) method. Eur J Pharmaceut Sci. 2005; 24(4): 333-349. https://doi.org/10.1016/J.EJPS.2004.11.011

[63] Hassanzadeh P, Atyabi F, Dinarvand R. The significance of artificial intelligence in drug delivery system design. Adv Drug Deliv Rev. 2019; 151-152: 169-190. https://doi.org/10.1016/J.ADDR.2019.05.001

[64] Luo M, Feng Y, Wang T, Guan J. Micro-/Nanorobots at work in active drug delivery. Adv Funct Mater. 2018; 28(25): 1706100-1706108. https://doi.org/10.1002/ADFM.201706100

[65] Fu J, Yan H. Controlled drug release by a nanorobot. Nat Biotechnol. 2012; 30(5): 407-408. https://doi.org/10.1038/NBT.2206

[66] Calzolari D, Bruschi S, Coquin L, et al. Search algorithms as a framework for the optimization of drug combinations. PLoS Comput Biol. 2008; 4(12):e1000256. https://doi.org/10.1371/JOURNAL.PCBI.1000249

[67] Tsigelny IF. Artificial intelligence in drug combination therapy. Briefings Bioinf. 2019; 20(4): 1434-1448. https://doi.org/10.1093/BIB/BBY004

[68] Wilson B, Km G. Artificial intelligence and related technologies enabled nanomedicine for advanced cancer treatment. Nanomedicine. 2020; 15(5): 433-435. https://doi.org/10.2217/NNM-2019-0366

[69] Li X, Xu Y, Cui H, et al. Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles. Artif Intell Med. 2017; 83: 35-43. https://doi.org/10.1016/J.ARTMED.2017.05.008

[70] Mason DJ, Eastman RT, Lewis RPI, Stott IP, Guha R, Bender A. Using machine learning to predict synergistic antimalarial compound combinations with novel structures. Front Pharmacol. 2018; 9(OCT): 392948-392961. https://doi.org/10.3389/FPHAR.2018.01096/BIBTEX

[71] Soltani M, Kashkooli FM, Souri M, et al. Enhancing clinical translation of cancer using nanoinformatics. Cancers (Basel). 2021; 13(10): 2481-2496. https://doi.org/10.3390/CANCERS13102481

[72] Mehta CH, Narayan R, Nayak UY. Computational modeling for formulation design. Drug Discov Today. 2019; 24(3): 781-788. https://doi.org/10.1016/J.DRUDIS.2018.11.018

[73] Ho D, Wang P, Kee T. Artificial intelligence in nanomedicine. Nanoscale Horizons. 2019; 4(2): 365-377. https://doi.org/10.1039/C8NH00233A

[74] Smith W. How Atomwise uses artificial intelligence for drug discovery | Technology Magazine. Technol Mag. 2020: 34-43. Published online.

[75] Zhavoronkov A. First generative AI drug begins phase II trials with patients. Insilico Med. 2023: 16-21. Published online.

[76] Wang L, Chen X, Zhang L, et al. Artificial intelligence in clinical decision support systems for oncology. Int J Med Sci. 2023; 20(1): 79-86. https://doi.org/10.7150/IJMS.77205

[77] Bhattacharya S, Saleem SM, Singh A, Singh S, Tripathi S. Empowering precision medicine: regenerative AI in breast cancer. Front Oncol. 2024; 14: 1465720-1465728. https://doi.org/10.3389/FONC.2024.1465720

[78] Paul V. Pharmacy Inventory Management Programs. McKesson. mckesson; 2023. Accessed April 10, 2025. https://www.mckesson.com/pharmacy-management/drug-inventory/

[79] Dignan L. CVS Health’s transformation rides on data, AI and customer experiences. Constell Res Inc. 2023: 1-6. Published online.

[80] Anna S. 23andMe Announces Collaboration Extension with a New Data. globenewswire; 2023. Accessed April 10, 2025. https://www.globenewswire.com/news-release/2023/10/30/2769169/0/en/23andMe-Announces-Collaboration-Extension-with-a-New-Data-Licensing-Agreement-with-GSK.html

[81] Viraswami-Appanna K, Buenconsejo J, Baidoo C, et al. Accelerating drug development at Bristol myers Squibb through innovation. Drug Discov Today. 2024; 29(5): 103952-103963. https://doi.org/10.1016/J.DRUDIS.2024.103952

[82] Uzoeto HO, Cosmas S, Bakare TT, Durojaye OA. AlphaFold-latest: revolutionizing protein structure prediction for comprehensive biomolecular insights and therapeutic advancements. Beni-Suef Univ J Basic Appl Sci. 2024; 13(1): 1-5. https://doi.org/10.1186/S43088-024-00503-Y

[83] Bess A, Berglind F, Mukhopadhyay S, et al. Artificial intelligence for the discovery of novel antimicrobial agents for emerging infectious diseases. Drug Discov Today. 2022; 27(4): 1099-1107. https://doi.org/10.1016/J.DRUDIS.2021.10.022

[84] Olawade DB, Aderinto N, Olatunji G, Kokori E, David-Olawade AC, Hadi M. Advancements and applications of Artificial Intelligence in cardiology: current trends and future prospects. J Med Surgery, Public Heal. 2024; 3:100117. https://doi.org/10.1016/J.GLMEDI.2024.100109

[85] Pons-Belda OD, Fernandez-Uriarte A, Diamandis EP. Can circulating tumor DNA support a successful screening test for early cancer detection? The grail paradigm. Diagnostics. 2021; 11(12): 2171-2179. https://doi.org/10.3390/DIAGNOSTICS11122171

[86] Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology. Nat Rev Clin Oncol. 2019; 16(11): 703-715. https://doi.org/10.1038/s41571-019-0252-y

[87] Zia A, Fletcher C, Bigwood S, et al. Retrospective analysis and prospective validation of an AI-based software for intracranial haemorrhage detection at a high-volume trauma centre. Sci Rep. 2022; 12(1): 19885-19894. https://doi.org/10.1038/S41598-022-24504-Y

[88] Aldughayfiq B, Sampalli S. Digital health in physicians’ and pharmacists’ office: a comparative study of e-prescription systems’ architecture and digital security in eight countries. OMICS. 2021; 25(2): 102-122. https://doi.org/10.1089/OMI.2020.0085

[89] Kanyongo W, Ezugwu AE. Machine learning approaches to medication adherence amongst NCD patients: a systematic literature review. Inform Med Unlocked. 2023; 38: 101210-101219. https://doi.org/10.1016/J.IMU.2023.101210

[90] Babel A, Taneja R, Mondello Malvestiti F, Monaco A, Donde S. Artificial intelligence solutions to increase medication adherence in patients with non-communicable diseases. Front Digit Heal. 2021; 3: 669869-669876. https://doi.org/10.3389/FDGTH.2021.669869

[91] khan B, Fatima H, Qureshi A, et al. Drawbacks of artificial intelligence and their potential solutions in the healthcare sector. Biomed Mater Devices. 2023; 1(2): 8-738. https://doi.org/10.1007/S44174-023-00063-2

[92] Fahim MIA, Tonny TS, Al Noman A. Realizing the potential of AI in pharmacy practice: barriers and pathways to adoption. Intell Pharm. 2024; 2(3): 308-311. https://doi.org/10.1016/J.IPHA.2024.02.003

[93] Sujith T, Chakradhar T, Sravani M, Sowmini K. Aspects of utilization and limitations of artificial intelligence in drug safety. Asian J Pharmaceut Clin Res. 2021; 14(8): 34-39. https://doi.org/10.22159/AJPCR.2021.V14I8.41979

[94] Sonia DF. Ul ain. Healing horizons: AI and ML innovations in pharmaceuticals. ShodhKosh J Vis Perform Arts. 2022; 3(2). 609-617-609-617. https://doi.org/10.29121/SHODHKOSH.V3.I2.2022.2241

[95] Babashahi L, Barbosa CE, Lima Y, et al. AI in the workplace: a systematic review of skill transformation in the industry. Adm Sci. 2024; 14(6): 127-139. https://doi.org/10.3390/ADMSCI14060127

[96] Siri G. Overcoming challenges: ensuring data privacy and security in AI-driven pharma. Mintage J Pharm Med Sci. 2024; 13(2): 7. https://doi.org/10.4303/2320-3315/236013

[97] Kolluri S, Lin J, Liu R, Zhang Y, Zhang W. Machine learning and artificial intelligence in pharmaceutical research and development: a review. AAPS J. 2022; 24(1): 19-32. https://doi.org/10.1208/S12248-021-00644-3

[98] Tilala MH, Chenchala PK, Choppadandi A, et al. Ethical considerations in the use of artificial intelligence and machine learning in health care: a comprehensive review. Cureus. 2024; 16(6): e62443-e62458. https://doi.org/10.7759/CUREUS.62443

[99] Lu X, Yang C, Liang L, Hu G, Zhong Z, Jiang Z. Artificial intelligence for optimizing recruitment and retention in clinical trials: a scoping review. J Am Med Inf Assoc. 2024; 31(11): 2749-2763. https://doi.org/10.1093/JAMIA/OCAE243

[100] Johnson KB, Wei WQ, Weeraratne D, et al. Precision medicine, AI, and the future of personalized health care. Clin Transl Sci. 2020; 14(1): 86-93. https://doi.org/10.1111/CTS.12884

[101] Huanbutta K, Burapapadh K, Kraisit P, et al. Artificial intelligence-driven pharmaceutical industry: a paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. Eur J Pharmaceut Sci. 2024; 203:106938. https://doi.org/10.1016/J.EJPS.2024.106938

[102] Singh A. Artificial intelligence for drug repurposing against infectious diseases. Artif Intell Chem. 2024; 2(2): 100071-100082. https://doi.org/10.1016/J.AICHEM.2024.100071

[103] Ali MS, Ahsan MM, Tasnim L, et al. Federated learning in healthcare: model misconducts, security, challenges, applications, and future research directions -- A systematic review. Int J Comput Appl Technol Res. 2024; 14(4): 16-29.

[104] Yadav S, Singh A, Singhal R, Yadav JP. Revolutionizing drug discovery: the impact of artificial intelligence on advancements in pharmacology and the pharmaceutical industry. Intell Pharm. 2024; 2(3): 367-380. https://doi.org/10.1016/J.IPHA.2024.02.009

[105] Saini JPS, Thakur A, Yadav D. AI-driven innovations in pharmaceuticals: optimizing drug discovery and industry operations. RSC Pharm. 2025; 4(7): 33-47. https://doi.org/10.1039/D4PM00323C

[106] Alum EU. AI-driven biomarker discovery: enhancing precision in cancer diagnosis and prognosis. Discov Oncol. 2025; 16(1): 109-118. https://doi.org/10.1007/S12672-025-02064-7

[107] Fu C, Chen Q. The future of pharmaceuticals: artificial intelligence in drug discovery and development. J Pharm Anal. 2025:101248. Published online February 26. https://doi.org/10.1016/J.JPHA.2025.101248

[108] Takase T, Muroi N, Hashida T. Use of robotics and AI to transform dispensing and drug therapy as well as shaping the future of pharmacy education in Japan. J Asian Assoc Sch Pharm. 2025; 14(1): 8-13. https://doi.org/10.62100/jaasp.2025.14102

RIGHTS & PERMISSIONS

2025 The Author(s). Journal of Intelligent Medicine published by John Wiley & Sons Australia, Ltd on behalf of Tianjin University.